CA2773353C - Oligomer-calcimimetic conjugates and related compounds - Google Patents
Oligomer-calcimimetic conjugates and related compounds Download PDFInfo
- Publication number
- CA2773353C CA2773353C CA2773353A CA2773353A CA2773353C CA 2773353 C CA2773353 C CA 2773353C CA 2773353 A CA2773353 A CA 2773353A CA 2773353 A CA2773353 A CA 2773353A CA 2773353 C CA2773353 C CA 2773353C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- daltons
- lower alkyl
- oligomer
- cinacalcet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyethers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24693109P | 2009-09-29 | 2009-09-29 | |
| US61/246,931 | 2009-09-29 | ||
| PCT/US2010/050761 WO2011056325A2 (en) | 2009-09-29 | 2010-09-29 | Oligomer-calcimimetic conjugates and related compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2773353A1 CA2773353A1 (en) | 2011-05-12 |
| CA2773353C true CA2773353C (en) | 2018-02-27 |
Family
ID=43901165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2773353A Active CA2773353C (en) | 2009-09-29 | 2010-09-29 | Oligomer-calcimimetic conjugates and related compounds |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2482855B1 (https=) |
| JP (1) | JP5792175B2 (https=) |
| KR (1) | KR101828613B1 (https=) |
| CN (1) | CN102573921B (https=) |
| AU (1) | AU2010315805B2 (https=) |
| CA (1) | CA2773353C (https=) |
| IL (1) | IL218869A (https=) |
| MX (1) | MX341690B (https=) |
| WO (1) | WO2011056325A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
| JP2020105072A (ja) * | 2017-03-24 | 2020-07-09 | 協和キリン株式会社 | ポリエチレングリコール誘導体 |
| US20220040318A1 (en) * | 2018-09-28 | 2022-02-10 | Seikagaku Corporation | Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor |
| KR20230066044A (ko) * | 2020-09-10 | 2023-05-12 | 샨시 마이콧 테크놀로지 컴퍼니 리미티드 | 이중특이적 융합 폴리펩타이드 화합물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966988A (en) | 1989-02-17 | 1990-10-30 | Chevron Research Company | Process for preparing acetonitrile 3-trifluoromethyl benzene |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6211244B1 (en) | 1994-10-21 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5648541A (en) | 1995-09-28 | 1997-07-15 | Nps Pharmaceuticals, Inc. | Chiral reductions of imines leading to the syntheses of optically active amines |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| EP2905033B1 (en) * | 2003-12-16 | 2020-09-02 | Nektar Therapeutics | Monodisperse PEGylated naloxol compositions |
| WO2006125026A2 (en) | 2005-05-16 | 2006-11-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing cinacalcet hydrochloride |
| BRPI0611872B8 (pt) | 2005-06-16 | 2021-05-25 | Nektar Therapeutics | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica |
| US7563930B2 (en) | 2005-11-22 | 2009-07-21 | Teva Pharmaceutical Industries Ltd | Crystal forms of Cinacalcet HCI and processes for their preparation |
| TW200811082A (en) | 2006-04-27 | 2008-03-01 | Teva Pharma | Process for the preparation of cinacalcet base |
| CA2681582C (en) * | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
| WO2009151590A2 (en) * | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Methods of treating cyp2d6 alternative metabolizers |
-
2010
- 2010-09-29 KR KR1020127005885A patent/KR101828613B1/ko active Active
- 2010-09-29 MX MX2012003775A patent/MX341690B/es active IP Right Grant
- 2010-09-29 CA CA2773353A patent/CA2773353C/en active Active
- 2010-09-29 JP JP2012531124A patent/JP5792175B2/ja active Active
- 2010-09-29 EP EP10810996.8A patent/EP2482855B1/en active Active
- 2010-09-29 WO PCT/US2010/050761 patent/WO2011056325A2/en not_active Ceased
- 2010-09-29 CN CN201080043400.0A patent/CN102573921B/zh active Active
- 2010-09-29 AU AU2010315805A patent/AU2010315805B2/en active Active
-
2012
- 2012-03-27 IL IL218869A patent/IL218869A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013505966A (ja) | 2013-02-21 |
| EP2482855B1 (en) | 2017-12-27 |
| CA2773353A1 (en) | 2011-05-12 |
| WO2011056325A3 (en) | 2011-09-29 |
| JP5792175B2 (ja) | 2015-10-07 |
| MX341690B (es) | 2016-08-29 |
| CN102573921A (zh) | 2012-07-11 |
| KR101828613B1 (ko) | 2018-02-12 |
| AU2010315805B2 (en) | 2015-09-17 |
| IL218869A0 (en) | 2012-06-28 |
| KR20120090961A (ko) | 2012-08-17 |
| CN102573921B (zh) | 2015-11-25 |
| MX2012003775A (es) | 2012-06-12 |
| EP2482855A2 (en) | 2012-08-08 |
| IL218869A (en) | 2016-12-29 |
| WO2011056325A2 (en) | 2011-05-12 |
| AU2010315805A1 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9233169B2 (en) | Oligomer-bis-chromonyl compound conjugates | |
| WO2012083153A1 (en) | Oligomer-containing apremilast moiety compounds | |
| US9399033B2 (en) | Oligomer-containing pyrrolidine compounds | |
| CA2773353C (en) | Oligomer-calcimimetic conjugates and related compounds | |
| US10265411B2 (en) | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | |
| WO2008112287A1 (en) | Oligomer-beta blocker conjugates | |
| US20130338204A1 (en) | Oligomer-Dantrolene Conjugates and Related Compounds | |
| EP2134370A1 (en) | Oligomer-anticholinergic agent conjugates | |
| US9617228B2 (en) | Oligomer-containing substituted aromatic triazine compounds | |
| US9421275B2 (en) | Oligomer-calcimimetic conjugates and related compunds | |
| US9487473B2 (en) | Oligomer-amino acid conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150831 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250811 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251008 |